Efficacy and safety of <scp>DBPR108</scp> (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase <scp>III</scp> clinical trial-Reference-Cited by-同舟云学术

Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial

Published:2022-07-22 Issue:11 Volume:24 Page:2232-2240
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Xu Jianping¹^ORCID,Ling Hongwei²,Geng Jianlin³,Huang Yanli⁴,Xie Ying⁴,Zheng Huiping⁴,Niu Huikun⁴,Zhang Tianhao⁴,Yuan Jing⁴,Xiao Xinhua¹,

Affiliation:

1. Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital Peking Union Medical College, Chinese Academy of Medical Sciences Beijing China

2. Department of Endocrinology The Affiliated Hospital of Xuzhou Medical University Xuzhou China

3. Department of Endocrinology Harrison International Peace Hospital Hengshui China

4. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Shijiazhuang China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14810

Reference28 articles.

1. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial

2. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition);Chinese Diabetes Society;Chin J Diabetes.,2021

3. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

4. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

5. (2S,4S)-1-[2-(1,1-Dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

2. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM);European Journal of Medicinal Chemistry;2024-06

3. A Phase I Clinical Study of the Pharmacokinetics and Safety of Prusogliptin Tablets in Subjects with Mild to Moderate Hepatic Insufficiency and Normal Liver Function;Current Drug Metabolism;2024-02

4. Prusogliptin (DBPR108) monotherapy in treatment‐naïve patients with type 2 diabetes: A randomized, double‐blind, active and placebo‐controlled, phase 3 study;Diabetes, Obesity and Metabolism;2024-01-15

5. Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study;Diabetes, Obesity and Metabolism;2023-05-03